相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abstract A6: RNAseq and immune profiling analysis of syngeneic mouse models treated with immune checkpoint inhibitors enable biomarker discovery and model selection for cancer immunotherapy
Lan Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
Amer Assal et al.
IMMUNOTHERAPY (2015)
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Formulation and Stability of Cytokine Therapeutics
Tiina Lipiainen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Release the Hounds! Activating the T-Cell Response to Cancer
Mario Sznol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
Isabelle Le Mercier et al.
FRONTIERS IN IMMUNOLOGY (2015)
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
Roxanne Payne et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Mathematical models of the impact of IL2 modulation therapies on T cell dynamics
Kalet Leon et al.
FRONTIERS IN IMMUNOLOGY (2013)
Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies
Karina Garcia-Martinez et al.
INTERNATIONAL IMMUNOLOGY (2012)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo
Vandana Kalia et al.
IMMUNITY (2010)
Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response
Ofer Feinerman et al.
MOLECULAR SYSTEMS BIOLOGY (2010)
IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25
Sven Letourneau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments
Dorothea Busse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics
C. Simone Fishburn
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
ReGel® polymer-based delivery of interleukin-2 as a cancer treatment
Wolfram E. Samlowski et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor
DJ Stauber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
Thrombotic thrombocytopenic ourpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma
DT Alexandrescu et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy
GW Bos et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its α, β, and γc receptors
M Rickert et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
The shape of the messenger: Using protein structure information to design novel cytokine-based therapeutics
CH Schein
CURRENT PHARMACEUTICAL DESIGN (2002)
An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected rhesus monkeys
A Craiu et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2001)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
